CRS ImmunoDelivery Focus Group Best Abstract Award to Jiahui Li
Jiahui Li, a PhD student in Molecular Pharmaceutics (Kopeček/Yang Lab), has been awarded the Best Abstract Award by the Controlled Release Society ImmunoDelivery Focus Group. The award was presented during the group’s meeting on July 14, 2025. As part of the recognition, Jiahui was invited to give an overview of her research.
Jiahui's abstract highlights her work on a CD47-targeted antibody HPMA polymer-drug conjugate designed for the treatment of ovarian cancer. This dual-function therapeutic not only delivers the chemotherapy drug paclitaxel directly to cancer cells, but also blocks CD47—an immune checkpoint that allows tumors to escape immune detection. Her findings demonstrate that the therapy triggers both direct tumor cell death and an immune response by enhancing macrophage activity and promoting immunogenic cell death.
Reflecting on the experience, Jiahui stated, “It was very exciting for me to share my work, especially as part of the ImmunoDelivery Focus Group. I had the opportunity to present my research to others in the field, receive constructive feedback, and engage in meaningful conversations. It was a valuable experience—not just to showcase my findings, but also to connect with researchers who are equally passionate about advancing science.”
